Bharat biotech's COVID-19 vaccine Covaxin gets DCGI nod for phase 3 clinical trial
The vaccine 'Covaxin' is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Clinical Trials | COVID-19 | India Health | Pharmaceuticals | Research | Vaccines